366 related articles for article (PubMed ID: 12180114)
41. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
[TBL] [Abstract][Full Text] [Related]
42. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
43. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
44. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
[TBL] [Abstract][Full Text] [Related]
45. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
[TBL] [Abstract][Full Text] [Related]
46. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
[TBL] [Abstract][Full Text] [Related]
47. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
[TBL] [Abstract][Full Text] [Related]
48. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
49. Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors.
Redei I; Langston AA; Lonial S; Cherry JK; Allen AJ; Hamilton E; Jones M; Bartlett VM; Waller EK
Bone Marrow Transplant; 2002 Sep; 30(6):335-40. PubMed ID: 12235516
[TBL] [Abstract][Full Text] [Related]
50. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
51. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
[TBL] [Abstract][Full Text] [Related]
53. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
54. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
55. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
[TBL] [Abstract][Full Text] [Related]
56. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
[TBL] [Abstract][Full Text] [Related]
57. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
58. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Devillier R; Crocchiolo R; Castagna L; Fürst S; El Cheikh J; Faucher C; Prebet T; Etienne A; Chabannon C; Vey N; Esterni B; Blaise D
Bone Marrow Transplant; 2012 May; 47(5):639-45. PubMed ID: 22307016
[TBL] [Abstract][Full Text] [Related]
59. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
60. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
